Degarelix

Degarelix competitively blocks GnRH receptors without receptor activation, immediately preventing LH and FSH release. Unlike GnRH agonists that first activate then desensitize receptors, degarelix occupies receptors without generating cAMP signal, producing instantaneous gonadotropin suppression. This means testosterone begins falling within hours of the loading dose and reaches castrate levels (<50 ng/dL) in >95% of patients within 3 days. LH and FSH remain suppressed throughout monthly maintenance dosing.

The key distinction from GnRH agonists: degarelix produces no testosterone flare. With leuprolide or other agonists, the initial receptor activation before desensitization causes testosterone to surge 50-100% above baseline for 1-2 weeks, risking flare-related complications. Degarelix eliminates this window entirely. Additionally, GnRH antagonism maintains more physiological LH pulsatility characteristics in the transition to suppression, potentially affecting downstream hormonal milieu differently.

GnRH receptors are expressed on prostate cancer cells, and degarelix direct receptor blockade may produce anti-tumor effects beyond testosterone suppression. In vitro data suggests degarelix directly reduces prostate cancer cell viability via GnRH receptor-mediated apoptosis. Clinically, degarelix achieves faster PSA declines than leuprolide. Immune-modulatory differences between agonists and antagonists are being studied, with potential implications for combining ADT with checkpoint immunotherapy.

Phase III CS21 trial (n=610) showed degarelix non-inferior to leuprolide for testosterone suppression at 1 year (97% vs 96% maintained castrate levels). PSA decreased faster with degarelix. A key finding: degarelix-treated patients had significantly fewer musculoskeletal events (fractures, spinal cord compression) than leuprolide-treated patients in the first year, supporting the absence of flare as clinically meaningful.

Observational and post-hoc data suggest degarelix may be associated with lower major adverse cardiovascular events (MACE) compared to GnRH agonists, particularly in patients with pre-existing cardiovascular disease. The PRONOUNCE trial (randomized comparison) did not show a statistically significant difference, but the hypothesis remains active in meta-analyses. GnRH receptor expression on cardiac tissue and direct cardiac effects of antagonism vs agonism are mechanistic areas of ongoing study.

Degarelix's rapid castration onset makes it valuable for neoadjuvant ADT before radiation or surgery where rapid testosterone suppression is clinically beneficial. Studies combining degarelix with enzalutamide, abiraterone, or PARP inhibitors are ongoing, leveraging rapid castration as a foundation for combination regimens. The faster PSA kinetics on degarelix versus agonists are being evaluated as predictive biomarkers.